Historical concepts of Alzheimer’s disease and dementia

Atlas of Alzheimer’s Disease

Volumn , Issue , 2007, Pages 1-26

  Grand, Jacob ^a   Feldman, Howard H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954352071     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781435626133-1     Document Type: Chapter

References (48)

1. Schafer D. ‘That senescence itself is an illness’: a transitional medical concept of age and ageing in the eighteenth century. Med Hist, 2002; 46: 525-48.
2. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol Aging, 1998; 19:173-89.
3. Halpert BP. Development of the term ‘senility’ as a medical diagnosis. Minn Med, 1983; 66: 421-4.
4. Boller F, Forbes MM. History of dementia and dementia in history: an overview. J Neurol Sci, 1998; 158: 125-33.
5. Beach TG. The history of Alzheimer’s disease: three debates. J Hist Med Allied Sci, 1987; 42: 327-49.
6. Graeber MB, Mehraein P. Reanalysis of the first case of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci, 1999; 249 (Suppl 3): 10-13.
7. Berrios GE. Alzheimer’s disease: A conceptual history. Int J Geriatr Psychiatry, 1990; 5 (6): 355-65.
8. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. Lancet, 1997; 349: 1546-9.
9. Amaducci LA, Rocca WA, Schoenberg BS. Origin of the distinction between Alzheimer’s disease and senile dementia:how history can clarify nosology. Neurology, 1986; 36:1497-9.
10. Graeber MB, Kosel S, Egensperger R et al. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics, 1997; 1: 73-80.
11. Holstein M. Alzheimer’s disease and senile dementia, 1885-1920: An interpretive history of disease negotiation. J Aging Studies, 1997; 11(1): 1-13.
12. Katzman R. Alzheimer’s disease. N Engl J Med, 1986; 314:964-73.
13. Katzman R, Jackson JE. Alzheimer disease: basic and clinical advances. J Am Geriatr Soc, 1991; 39: 516-25.
14. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci, 1968; 7: 331-56.
15. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci, 1970; 11: 205-42.
16. Whitehouse PJ, Price DL, Struble RG. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982; 215: 1237-39.
17. Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type. Clinical genetics, natural history, and associated conditions. Arch Gen Psychiatry, 1981; 38: 1085-90.
18. Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun, 1984; 122:1131-5.
19. Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature, 1987; 325: 733-6.
20. St George-Hyslop P, Haines J, Rogaev E et al. Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14. Nat Genet, 1992; 2: 330-4.
21. Levy-Lahad E, Wijsman EM, Nemens E et al. A familial Alzheimer’s disease locus on chromosome 1. Science, 1995; 269: 970-3.
22. Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell, 2005; 120: 545-55.
23. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer’s disease. Neurology, 1993; 43: 1467-72.
24. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apoliprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 1993; 261: 921-3.
25. Foster NL, Wilhelmsen K, Sima AA et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41: 706-15.
26. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci, 1991; 12(10): 383-8.
27. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science, 1992; 256: 184-5.
28. Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 1996; 274: 99-102.
29. Pereira C, Agostinho P, Moreira PI, Cardoso SM, Oliveira CR. Alzheimer’s disease-associated neurotoxic mechanisms and neuroprotective strategies. Curr Drug Targets CNS Neurol Disord, 2005; 4: 383-403.
30. Scheltens P, Korf ES. Contribution of neuroimaging in the diagnosis of Alzheimer’s disease and other dementias. Curr Opin Neurol, 2000; 13: 391-6.
31. Agdeppa ED, Kepe V, Liu J et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci, 2001; 21: RC189.
32. Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol, 2004; 3: 519-27.
33. APA (American Psychiatric Association). Diagnostic and Statistical Manual of Mental Disorders, DSM-III-R edn. Washington, DC: American Psychiatric Association, 1987.
34. McKhann G, Drachman DA, Folstein M et al. Clinical diagnosis of Alzheimer’s disease-Report of the NINCDSAAD ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 1984; 34: 939-44.
35. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol, 1985; 42: 1097-105.
36. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease [editorial]. J Neuropathol Exp Neurol, 1997; 56: 1095-7.
37. Folstein MF, Folstein S, McHugh PR. Mini-mental state:a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975; 12: 189-98.
38. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry, 1984; 141 (11):1356-64.
39. Sheikh K, Smith DS, Meade TW et al. Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability. Int Rehabil Med, 1979; 1: 51-8.
40. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer’s disease: The Disability Assessment for Dementia. Am J Occup Ther, 1999; 53: 471-81.
41. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory (NPI). Neurology, 1994; 44: 2308-14.
42. Reisberg B, Borenstein J, Salob SP. Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry, 1987; 48(Suppl): 9-15.
43. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology, 1994; 44: 2315-21.
44. Hughes CP, Berg L, Danzinger WL. A new clinical scale for the staging of dementia. Bri J Psychiatry, 1982; 140: 566-72.
45. Peters BH, Levin HS. Effects of physotigmine and lecithin on memory in Alzheimer disease. Ann Neurol, 1979; 6(3): 219-21.
46. Bliss TV, Collingridge GL. A synaptic model of memory:long-term potentiation in the hippocampus. Nature, 1993; 361: 31-9.
47. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci, 1996; 17: 348-55.
48. Areosa Sastre A, Sherriff F, McShane R. Memantine for Dementia. The Cochrane Database of Systematic Reviews. 25-5-2005.